Sanofi terminates development of otamixaban in ACS

Topline results of the completed Phase III study of the investigational anticoagulant otamixaban from Sanofi showed the study did not meet its primary endpoint of superiority over current therapy. In the TAO study (Treatment of non-ST elevation Acute coronary syndrome with otamixaban), due to efficacy lower than expected, otamixaban did not show superior benefit/risk to the combination of unfractionated heparin (UFH) +/- eptifibatide (a GP IIb/IIIa inhibitor) in non-ST elevation Acute Coronary Sndrome (NSTE-ACS) patients planned for early invasive strategy.

The primary endpoint of the Phase III TAO study was the reduction of all-cause mortality or new heart attacks. Following the results of the TAO study the company has decided to discontinue the investigational program with otamixaban, an injectable factor Xa inhibitor.